High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction

Stroke

Volumn 40, Issue 10, 2009, Pages 3233-3237

  Elkind, Mitchell S V ^a   Leon, Vladimir ^a   Moon, Yeseon P ^a   Paik, Myunghee C ^b   Sacco, Ralph L ^c  

^a Columbia University ^*  (United States)

^b University of Miami ^*  (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; C reactive protein; Inflammation; Ischemic stroke; Myocardial infarction

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN;

AGED; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME STABILITY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SERUM; STROKE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOWN-REGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STROKE; TIME FACTORS;

EID: 70349686737     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.552802     Document Type: Article

References (22)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Oei HHS, van den Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, Witteman JCM. Lipoprotein-phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation. 2005;111:570-575.
3. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A2, plateletactivating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413-419.
4. Bogaty P, Brophy JM, Boyer L, Simard S, Joseph L, Bertrand F, Dagenais GR. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med. 2005;165:221-226.
5. Di Napoli M, Schwaninger M, Cappeli R, Ceccarelli E, Di Gianfilippo G, Donati C, Emsley HC, Forconi S, Sander D, Sander K, Smith CJ, Stefanini A, Weber D. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005; 36:1316-1329.
6. Elkind MSV, Tai W, Coates K, Paik MC, Sacco RL. Lipoproteinassociated phospholipase A2, C-reactive protein, and outcome after ischemic stroke. Arch Int Med. 2006;166:2073-2080.
7. Elkind MSV, Coates K, Tai W, Paik MC, Boden-Albala B, Sacco RL. Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurology. 2006;6:37.
8. Sacco RL, Anand K, Lee HS, Boden-Albala B, Stabler S, Allen R, Paik MC. Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study. Stroke. 2004;35:2263-2269.
9. Gentry EM, Kalsbeek WD, Hegelin G, Jones JT, Gaines KL, Forman MR, Marks JS, Trowbridge FL. The Behavioral Risk Factor Surveys: II. Design, methods, and estimates from combined state data. Am J Prev Med. 1985;1:9-14.
10. Packard CJ, O'Reilly DSJ, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GDO. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148-1155.
11. Iribarren C, Gross MD, Darbinian JA, Jacobs DR Jr, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol. 2005;25:216-221.
12. Elkind MSV, Tai W, Coates K, Paik MC, Sacco RL. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis. 2009;27:42-50.
13. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, McConnell JP. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006;9: 138-143.
14. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Amer J Cardiol. 2008;101:41F-50F.
15. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54: 24-38.
16. Elkind MSV. Inflammation, atherosclerosis, and stroke. The Neurologist. 2006;12:140-148.
17. Kayaba K, Ishikawa S, Gotoh T, Nago N, Kajii E, Nakamura Y, Kario K. Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993-1998. Jpn Circ J. 2000;64:303-308.
18. Alley DE, Crimmins E, Bandeen-Roche K, Guralnik J, Ferrucci L. Three-year change in inflammatory markers in elderly people and mortality: the Invecchiare in Chianti study. J Am Geriatr Soc. 2007;55: 1801-1807.
19. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice A statement for healthcare professionals from the Centers for Disease Control and Prevention and the Am Heart Association. Circulation. 2003;107: 499-511.
20. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006;113:1745-1752.
21. Albert MA, Glynn RJ, Wolfert RL, Ridker PM. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis. 2005; 182:193-198.
22. Kargman DE, Tuck C, Berglund L, Lin IF, Mukherjee RS, Thompson EV, Jones J, Boden-Albala B, Paik MC, Sacco RL. Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. Atherosclerosis. 1998;139:391-399.